Literature DB >> 11741833

Pathological mutations in TSC1 and TSC2 disrupt the interaction between hamartin and tuberin.

A K Hodges1, S Li, J Maynard, L Parry, R Braverman, J P Cheadle, J E DeClue, J R Sampson.   

Abstract

Critical functions of hamartin and tuberin, encoded by the TSC1 and TSC2 genes, are likely to be closely linked. The proteins interact directly with one another and mutations affecting either gene result in the tuberous sclerosis phenotype. However, the regions of hamartin and tuberin that interact have not been well defined, and the relationship between their interaction and the pathogenesis of tuberous sclerosis has not been explored. To address these issues a series of hamartin and tuberin constructs were used to assay for interaction in the yeast two-hybrid system. Hamartin (amino acids 302-430) and tuberin (amino acids 1-418) interacted strongly with one another. A region of tuberin encoding a putative coiled-coil (amino acids 346-371) was necessary but not sufficient to mediate the interaction with hamartin, as more N-terminal residues were also required. A region of hamartin (amino acids 719-998) predicted to encode coiled-coils was capable of oligermerization but was not important for the interaction with tuberin. Subtle, non-truncating mutations identified in patients with tuberous sclerosis and located within the putative binding regions of hamartin (N198_F199delinsI;593-595delACT) or tuberin (G294E and I365del), abolished or dramatically reduced interaction of the proteins as assessed by yeast two-hybrid assays and by co-immunoprecipitation of the full-length proteins from Cos7 cells. In contrast, three non-pathogenic missense polymorphisms of tuberin (R261W, M286V, R367Q) in the same region as the disease-causing TSC2 mutations did not. These results indicate a requirement for interaction in critical growth suppressing functions of hamartin and tuberin.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11741833     DOI: 10.1093/hmg/10.25.2899

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  27 in total

1.  Modulation of cell migration and invasiveness by tumor suppressor TSC2 in lymphangioleiomyomatosis.

Authors:  Elena A Goncharova; Dmitriy A Goncharov; Poay N Lim; Daniel Noonan; Vera P Krymskaya
Journal:  Am J Respir Cell Mol Biol       Date:  2005-12-30       Impact factor: 6.914

Review 2.  Lymphangioleiomyomatosis: A Monogenic Model of Malignancy.

Authors:  Vera P Krymskaya; Francis X McCormack
Journal:  Annu Rev Med       Date:  2017-01-14       Impact factor: 13.739

3.  Tsc2, a positional candidate gene underlying a quantitative trait locus for hepatic steatosis.

Authors:  Chen-Yu Wang; Donald S Stapleton; Kathryn L Schueler; Mary E Rabaglia; Angie T Oler; Mark P Keller; Christina M Kendziorski; Karl W Broman; Brian S Yandell; Eric E Schadt; Alan D Attie
Journal:  J Lipid Res       Date:  2012-05-23       Impact factor: 5.922

4.  Structure of the Tuberous Sclerosis Complex 2 (TSC2) N Terminus Provides Insight into Complex Assembly and Tuberous Sclerosis Pathogenesis.

Authors:  Reinhard Zech; Stephan Kiontke; Uwe Mueller; Andrea Oeckinghaus; Daniel Kümmel
Journal:  J Biol Chem       Date:  2016-08-04       Impact factor: 5.157

5.  Inactivation of MTOR promotes autophagy-mediated epithelial injury in particulate matter-induced airway inflammation.

Authors:  Yin-Fang Wu; Zhou-Yang Li; Ling-Ling Dong; Wei-Jie Li; Yan-Ping Wu; Jing Wang; Hai-Pin Chen; Hui-Wen Liu; Miao Li; Ci-Liang Jin; Hua-Qiong Huang; Song-Min Ying; Wen Li; Hua-Hao Shen; Zhi-Hua Chen
Journal:  Autophagy       Date:  2019-06-16       Impact factor: 16.016

6.  Abnormal growth of smooth muscle-like cells in lymphangioleiomyomatosis: Role for tumor suppressor TSC2.

Authors:  Elena A Goncharova; Dmitriy A Goncharov; Matthew Spaits; Daniel J Noonan; Ekaterina Talovskaya; Andrew Eszterhas; Vera P Krymskaya
Journal:  Am J Respir Cell Mol Biol       Date:  2006-01-19       Impact factor: 6.914

7.  A reliable cell-based assay for testing unclassified TSC2 gene variants.

Authors:  Ricardo Coevoets; Sermin Arican; Marianne Hoogeveen-Westerveld; Erik Simons; Ans van den Ouweland; Dicky Halley; Mark Nellist
Journal:  Eur J Hum Genet       Date:  2008-10-15       Impact factor: 4.246

8.  Update on the cytogenetics and molecular genetics of chordoma.

Authors:  Lidia Larizza; Pietro Mortini; Paola Riva
Journal:  Hered Cancer Clin Pract       Date:  2005-02-15       Impact factor: 2.857

9.  Conditional and domain-specific inactivation of the Tsc2 gene in neural progenitor cells.

Authors:  Cary Fu; Kevin C Ess
Journal:  Genesis       Date:  2013-03-13       Impact factor: 2.487

Review 10.  Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer.

Authors:  Margaret A Knowles; Fiona M Platt; Rebecca L Ross; Carolyn D Hurst
Journal:  Cancer Metastasis Rev       Date:  2009-12       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.